Alsevalimab is currently study as a experimental biological molecule targeting B7-H4. The immune-modulating treatment has shown preclinical effectiveness in multiple malignant diseases by blocking B7-H4 protein's https://2254029-91-7187995.blog-gold.com/60213694/alsevalimab-a-novel-anti-b7-h4-protein-in-clinical-trials